Literature DB >> 9588759

Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases.

U Eder1, B Leitner, R Kirchmair, P Pohl, K A Jobst, A D Smith, J Málly, A Benzer, P Riederer, H Reichmann, A Saria, H Winkler.   

Abstract

Human cerebrospinal fluid (CSF) contains chromogranin A and B and secretogranin II which represent peptides secreted from neuronal large dense core vesicles. Within these vesicles these precursor peptides are at least partly processed to smaller peptides. We analysed the CSF levels of chromogranins/secretogranin by radioimmunoassay using specific antisera. The degree of their processing was characterized by molecular sieve column chromatography followed by radioimmunoassay. As previously shown secretogranin II is fully processed to smaller peptides including the peptide secretoneurin, whereas processing of chromogranin A was more limited. For chromogranin B we found in this study a high degree of processing comparable to that of secretogranin II. An analysis of CSF from patients with multiple sclerosis, essential tremor, Alzheimer and Parkinson disease, did not reveal any differences in proteolytic processing of chromogranins/secretogranin when compared to control CSF. We conclude that in the four diseases investigated there is no change in the proteolytic processing of the chromogranins/secretogranin within the large dense core vesicles. The absolute levels of chromogranins/secretogranin varied in CSF collected in different hospitals, however their relative ratios were remarkable constant. We suggest to use this ratio as a parameter to standardise CSF levels of other peptides, e.g. neuropeptides. In Parkinson patients the chromogranin A/secretogranin II ratio was significantly increased whereas in Alzheimer patients and those with essential tremor and multiple sclerosis no change of the ratios was observed. Apparently there are only limited changes in the biosynthesis, processing, secretion and CSF clearance of these peptides in pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588759     DOI: 10.1007/s007020050036

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  8 in total

1.  8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.

Authors:  Leila Choe; Mark D'Ascenzo; Norman R Relkin; Darryl Pappin; Philip Ross; Brian Williamson; Steven Guertin; Patrick Pribil; Kelvin H Lee
Journal:  Proteomics       Date:  2007-10       Impact factor: 3.984

Review 2.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 3.  Chromogranin peptides in brain diseases.

Authors:  Michael Willis; Irmgard Leitner; Kurt A Jellinger; Josef Marksteiner
Journal:  J Neural Transm (Vienna)       Date:  2011-04-30       Impact factor: 3.575

4.  Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study.

Authors:  Michaela Kaiserová; Hana Přikrylová Vranová; David Stejskal; Kateřina Menšíková; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2013-04-16       Impact factor: 3.575

5.  Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.

Authors:  Anna Nilsson; Maria Fälth; Xiaoqun Zhang; Kim Kultima; Karl Sköld; Per Svenningsson; Per E Andrén
Journal:  Mol Cell Proteomics       Date:  2009-01-08       Impact factor: 5.911

Review 6.  Biomarker discovery in neurodegenerative diseases: a proteomic approach.

Authors:  Min Shi; W Michael Caudle; Jing Zhang
Journal:  Neurobiol Dis       Date:  2008-09-26       Impact factor: 5.996

7.  Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Authors:  Richard J Perrin; Rebecca Craig-Schapiro; James P Malone; Aarti R Shah; Petra Gilmore; Alan E Davis; Catherine M Roe; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Jeffrey A Kaye; John C Morris; David M Holtzman; R Reid Townsend; Anne M Fagan
Journal:  PLoS One       Date:  2011-01-12       Impact factor: 3.240

Review 8.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.